Xenetic Biosciences Advances Partnership with The Scripps Research Institute to Enhance Cancer Treatment

Xenetic Biosciences (XBIO) is advancing its partnership with The Scripps Research Institute to develop a systemic DNase I and CAR T-cell therapy for hematologic and solid tumors. The combination therapy has shown significant tumor reduction, reduced metastasis, and prolonged survival in preclinical studies. The program is expanding to include more lymphoma and leukemia models.

Xenetic Biosciences, Inc. (NASDAQ: XBIO), a biopharmaceutical company focused on innovative immuno-oncology technologies, has expanded its research collaboration with The Scripps Research Institute (TSRI) to further develop its systemic DNase I and CAR T-cell therapy for both hematologic and solid tumors. The company's systemic DNase I candidate, XBIO-015, is currently in preclinical development in combination with CAR-T cell therapy. Preliminary studies have demonstrated that co-administration of DNase I with CAR-T cells significantly reduces tumor burden, decreases metastatic lesions, and extends survival compared to CAR-T cell monotherapy [1].

The expanded research program will now include additional models of lymphoma and leukemia to further validate the findings. The DNase-based platform targets neutrophil extracellular traps (NETs) in the tumor microenvironment, which are web-like structures composed of extracellular chromatin coated with histones and other proteins. In cancer, NETs are expelled by activated neutrophils into the TME and blood, promoting cancer spread and local and systemic immunosuppression. Reduction of NETs burden via application of Xenetic's proprietary recombinant human DNase I has been shown to improve the efficacy of immunotherapy, adoptive cell therapy, and chemotherapy in preclinical animal models [1].

"We are pleased to further expand our collaboration with Scripps Research and explore the full potential of our DNase-based oncology platform," commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic. "The data generated to date continues to be encouraging and provides a compelling rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR-T cell therapy. We are grateful for the Scripps Research team and look forward to continuing to leverage their knowledge and expertise," Parslow added [1].

Xenetic continues to advance its DNase-based technology towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. The company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers [1].

References:
[1] https://www.xeneticbio.com/news-media/press-releases/detail/168/xenetic-biosciences-inc-expands-research-and-development
[2] https://www.stocktitan.net/news/XBIO/xenetic-biosciences-inc-expands-research-and-development-wr7qt9bofbfv.html